Tagged with R

Canada Fasken Canada’s Dara Jospe and Denis Douville examine Canada’s COVID-19 vaccine strategy, from the steps the country has taken to expedite the approval process to its funding of R&D projects and the preparations needed for ensuring the necessary supply and distribution infrastructure is in place.   Vaccination is a historically…

Global 2020 was a challenging year globally, but one in which the importance of the healthcare and life sciences sector was underlined like never before. Despite lockdowns and travel restrictions, PharmaBoardroom still managed to talk to key industry stakeholders from across the world helping shape the future of global health. Featured…

Global The top 10 most-read interviews on PharmaBoardroom in 2020 represents the broad geographic scope we have had in the past year. From Mexico to Morocco and Romania to Riyadh, these local insights help give a more well-rounded global picture of our industry today.   1. Bill Sibold, Executive VP, Sanofi…

Italy A roundup of some of the most important recent stories from Italian pharma, including an in-depth interview with Menarini CEO Elcin Barker Ergun, a public health management crisis in the south of the country, Chiesi’s latest mobile health partnership, and the potential rollout of COVID-19 vaccines in January 2021.  …

Switzerland Genomic medicine expert Professor Thomas D. Szucs explains what ignited his interest in the field and how payers and authorities are adapting to the strain on resources that genomic medicine can contribute to. Professor Szucs also evaluates the sustainability of personalized medicine and China’s rapid progress in the field.  …

Taiwan Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s COVID-19 vaccine strategy, and what MVC’s competitive advantages are. At MVC we have chosen a tried and tested technology platform as novel vaccine technologies face novel challenges Charles, could you start by introducing Medigen…

USA In a recent article for PharmaBoardroom, Objective Capital’s David Crean took a look at the state of US innovation today and its long term sustainability. See below for data on the share of US executives who see innovation as a top priority post-COVID, Global Public Equity Issuance for the Biopharmaceutical…

USA AAM President Dan Leonard highlights the findings of the association’s most recent report and re-states the value proposition of generic and biosimilar drugs in the USA.   AAM’s 2020 access and savings report documenting the savings generated by generic prescription drugs once again trumpets the value proposition of generic and…

Norway AbbVie Norway’s Kirsti Nyhus discusses access challenges in the Norwegian market for innovative drugs, the importance of bringing clinical trials back to Norway, managing through the COVID-19 pandemic, and establishing an award-winning working culture.   Norway has the opportunity to use its registries, pilot pay for performance schemes, and initiate…

Switzerland Prof Dr Jürg Utzinger of the Swiss Tropical and Public Health Institute (Swiss TPH) outlines the organisation’s important role within the global health landscape, how Switzerland collaborates with low- and middle-income countries, the growing significance of data, and what lessons can be taken from the COVID-19 crisis.   In a…

Europe On 25 November, the European Commission adopted a new strategy meant to, among others, allow Europe to cover its pharmaceutical needs, including in times of crisis, through robust supply chains. The strategy also contains a flagship actions to help curb the rise of antimicrobial resistance. Rex Clements, CEO of Centrient…

China The latest from Chinese pharma, including a drop in share prices for Chinese vaccine firms in the wake of successful COVID-19 trial results from western rivals, a new Pfizer-LianBio agreement, and Thermo Fisher’s new pharma services facility.   China pharma shares fall as western rivals lead in vaccine trials https://www.ft.com/content/c4c8453e-39f6-4aac-83a3-7d16a3f4fa4b…